Bayforest Capital Ltd Makes New $423,000 Investment in CRISPR Therapeutics AG $CRSP

Key Points

• Bayforest Capital Ltd has made a new investment of approximately $423,000 in CRISPR Therapeutics AG, acquiring 12,424 shares during the first quarter.
• Institutional investors collectively own 69.20% of CRISPR Therapeutics, with significant stake increases from firms like UBS AM and Millennium Management.
• CRISPR Therapeutics reported a quarterly loss of ($1.29) earnings per share, but beat estimates and had a revenue growth of 72.5% year-over-year.

Bayforest Capital Ltd bought a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,424 shares of the company's stock, valued at approximately $423,000.

Several other hedge funds have also made changes to their positions in CRSP. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in CRISPR Therapeutics by 182.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company's stock worth $66,452,000 after buying an additional 1,262,560 shares during the last quarter. Woodline Partners LP increased its holdings in shares of CRISPR Therapeutics by 34.3% in the 1st quarter. Woodline Partners LP now owns 136,483 shares of the company's stock worth $4,645,000 after acquiring an additional 34,883 shares during the period. Millennium Management LLC lifted its position in CRISPR Therapeutics by 6,769.1% in the 1st quarter. Millennium Management LLC now owns 583,733 shares of the company's stock valued at $19,864,000 after purchasing an additional 575,235 shares during the last quarter. AQR Capital Management LLC acquired a new position in CRISPR Therapeutics during the 1st quarter valued at about $861,000. Finally, Ancora Advisors LLC grew its position in CRISPR Therapeutics by 30.0% in the 1st quarter. Ancora Advisors LLC now owns 3,810 shares of the company's stock worth $130,000 after purchasing an additional 880 shares during the last quarter. Institutional investors own 69.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Barclays boosted their price target on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Piper Sandler reaffirmed an "overweight" rating and set a $105.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Chardan Capital reissued a "buy" rating and set a $82.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, August 5th. Royal Bank Of Canada lifted their target price on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a "sector perform" rating in a research note on Tuesday, August 5th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $81.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, July 8th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $71.60.

CRISPR Therapeutics Stock Down 0.8%

Shares of CRSP stock opened at $53.69 on Wednesday. The firm has a 50-day moving average price of $56.57 and a 200 day moving average price of $45.53. The company has a market capitalization of $4.88 billion, a P/E ratio of -9.89 and a beta of 1.81. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $71.13.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.18. The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. CRISPR Therapeutics's revenue was up 72.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.49) earnings per share. As a group, research analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, Director Simeon George purchased 989,812 shares of the company's stock in a transaction that occurred on Wednesday, July 16th. The stock was acquired at an average cost of $52.03 per share, with a total value of $51,499,918.36. Following the acquisition, the director owned 1,730,179 shares in the company, valued at approximately $90,021,213.37. This trade represents a 133.69% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.